We were pleased to attend the FDA/HESI Roadmap Planning on Hazard and Risk Assessment of Nitrosamine Impurities in Drugs workshop.
Organised by the FDA and HESI, this exciting event offered attendees the opportunity to engage in important discussions around the assessment of nitrosamines, including Nitrosamine Drug Substance-related Impurities (NDSRI).
Lhasa Principal Scientist, David Ponting presented on SAR Development and MOA to help set AIs, as part of the SAR collaboration he has been leading.